

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

DR. REDDY'S LABORATORIES S.A. AND
DR. REDDY'S LABORATORIES, INC.

Petitioners

v.

INDIVIOR UK LIMITED.

Patent Owner

U.S. PATENT NO. 9,687,454

TITLE: SUBLINGUAL AND BUCCAL FILM COMPOSITIONS

Case No. IPR2019-00328

**PETITION FOR *INTER PARTES* REVIEW OF
U.S. PATENT NO. 9,687,454**

Mail Stop PATENT BOARD
Patent Trial and Appeal Board
United States Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450

Table of Contents

	<u>Page</u>
I. INTRODUCTION	1
II. REQUIREMENTS FOR <i>INTER PARTES</i> REVIEW UNDER 37 C.F.R. § 42.104	3
A. Grounds for Standing	3
B. Identification of Challenge.....	3
III. TECHNOLOGY BACKGROUND.....	3
A. Buprenorphine and Naloxone.....	3
B. Suboxone® Tablets	4
C. Role of Buffers In Controlling the pH of Suboxone ® Tablets	5
IV. OVERVIEW OF THE '454 PATENT	6
A. Challenged Claims	6
B. The Delaware Court Invalidated Several Claims of the '832 Patent	7
C. Patent Owner Resumed Prosecution of the '454 Patent After the Delaware Court Decision	8
V. THE ASSERTED PRIOR ART PATENTS AND PUBLICATIONS	11
A. Euro-Celtique (Ex. 1007)	11
B. Fuisz (Ex. 1008)	12
C. Suboxone® PDR (Ex. 1009).....	12
D. EMEA (Ex. 1010).....	13
E. FDA IIG Database (Ex. 1011).....	13

VI. PERSON OF ORDINARY SKILL IN THE ART.....	14
VII. THE FDA IIG DATABASE AND THE EMEA QUALIFY AS PRINTED PUBLICATIONS.....	14
A. The FDA IIG Database Is a Printed Publication.....	14
1. The IIG Database Was Available as of December 2005	15
2. The IIG Database Was Both Indexed and Catalogued.	18
3. POSAs Would Have Known of FDA’s IIG Database and Had the Relevant Means to Access It.....	19
B. The EMEA Qualifies as a Printed Publication.....	22
VIII. CLAIM CONSTRUCTION.....	24
IX. DETAILED GROUNDS FOR UNPATENTABILITY: CLAIMS 1-3 AND 5-14 ARE OBVIOUS OVER EURO-CELTIQUE AND FUISZ IN VIEW OF THE SUBOXONE® PDR, EMEA, AND THE FDA IIG DATABASE.....	25
A. A POSA Would Have Been Motivated to Make Films Based on the Existing Suboxone® Tablet Formulation	25
1. Euro-Celtique motivated a POSA to make an oral film dosage form of Suboxone® tablets using the techniques disclosed in Fuisz.	26
2. A POSA would have been motivated to copy the acidic buffer in Suboxone® tablets.	27
3. Patent Owner is collaterally estopped from contesting that a POSA would have been motivated to copy the Suboxone® tablet’s buffer and pH and/or make a bioequivalent film version of Suboxone® tablets.....	32

B.	A POSA Would Have Had a Reasonable Expectation of Success in Making Films That Were Bioequivalent to Suboxone® Tablets.....	35
C.	Patent Owner Conceded That a POSA Would Have Had a Motivation to Formulate a Film Dosage Form That Was Bioequivalent to Suboxone® Tablets and Would Have Had a Reasonable Expectation of Success	37
D.	Independent Claim 1	41
1.	Euro-Celtique discloses the preamble.....	41
2.	Euro-Celtique discloses “about 40 wt % to about 60 wt % of a water-soluble polymer matrix” [1(a)]	41
3.	Euro-Celtique discloses “about 2mg to about 16 mg of buprenorphine or a pharmaceutically acceptable salt thereof” [1(b)].	42
4.	Euro-Celtique discloses “about 0.5 mg to about 4 mg of naloxone or a pharmaceutically acceptable salt thereof” [1(c)].	43
5.	Euro-Celtique and the Suboxone® PDR individually and in combination disclose “an acidic buffer” [1(d)]......	43
6.	Euro-Celtique teaches a film that is “mucoadhesive to the sublingual mucosa or the buccal mucosa” [1(e)]......	44
7.	Euro-Celtique and the Suboxone® PDR individually and in combination disclose a “weight ratio of [buprenorphine]:[naloxone] [of] about 4:1.” [1(f)]	45
8.	Euro-Celtique in combination with the FDA IIG database or alternatively routine experimentation discloses a “weight ratio of [buffer]:[buprenorphine] is from 2:1 to 1:5” (element 1(g)).	45

9.	Euro-Celtique in combination with the EMEA disclose the pharmacokinetic parameters in element 1(h).....	47
E.	Dependent Claims 2-3 and 5-14.....	48
1.	Euro-Celtique in combination with the FDA IIG database or alternatively routine experimentation discloses a “weight ratio of [buffer]:[buprenorphine] is from 1:1 to 1:5” (claim 2)	48
2.	Euro-Celtique in combination with the FDA IIG database or alternatively routine experimentation discloses a “weight ratio of [buffer]:[buprenorphine] is from 1.4:1 to 1:3” (claim 3) ...	48
3.	Euro-Celtique in combination with Fuisz discloses a “weight ratio of [buprenorphine]:[polymer]of from 1:3 to 1:11.5” (claim 5)	49
4.	Euro-Celtique in combination with Fuisz discloses a “weight ratio of [buprenorphine]:[polymer][of] about 1:3.” (claim 6) .	51
5.	Euro-Celtique discloses a film comprising “about 48.2 wt % to about 58.6 wt % of the water-soluble polymeric matrix” (claim 7)	51
6.	Euro-Celtique discloses a film comprising “about 48.2 wt % of the water-soluble polymeric matrix” (claim 8).....	52
7.	Euro-Celtique discloses a film “wherein the water-soluble polymer matrix comprises a polyethylene oxide polymer alone or in combination with a hydrophilic cellulosic polymer” (claim 9)	52
8.	Euro-Celtique discloses a film “wherein the hydrophilic cellulosic polymer is hydroxypropyl cellulose, hydroxypropylmethyl cellulose, or a combination thereof” (claim 10)	53

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.